The Centre for Cellular and Molecular Platforms (C-CAMP) announced on Tuesday that it has strengthened its collaboration with Agilent Technologies, a leading American laboratory technology firm. This expanded partnership provides a significantly larger number of Indian researchers with access to some of the world's most sophisticated drug-testing equipment, eliminating the need for them to purchase the costly instruments themselves.
This arrangement functions like a library for multimillion-dollar scientific instruments. The initiative is crucial because cutting-edge drug development has long been hindered by the high cost of specialized equipment. Small biotech startups and university researchers with promising ideas but limited budgets often had to forgo such tools or seek them abroad. According to C-CAMP, this partnership changes that dynamic by allowing researchers to book time on advanced machines located at its Bengaluru facility.
The collaboration has already yielded tangible results. In its initial phase, the partnership enabled Indian scientists to fully characterize Liraglutide, a drug widely used to treat diabetes and obesity, using equipment provided by Agilent. The work met international regulatory standards, marking a significant achievement for a molecule developed and tested entirely within India.
The expanded tie-up now covers a broader range of drug types, including complex biological medicines that are increasingly at the forefront of treatments for cancer, rare diseases, and infectious conditions. To kick off the new phase, the two organizations will conduct a training program for scientists from startups and industry, providing hands-on experience with the equipment.
Taslimarif Saiyed, Chief Executive of C-CAMP, emphasized that the partnership aims to democratize world-class science. He stated, "Such collaborations will play a key role in enabling technology development and accelerating science-led innovation." Nandakumar Kalathil, who heads Agilent's India operations, highlighted India's strategic importance to the company. He said, "India is a strategic priority for Agilent, and partnerships like this are central to how we expand access to critical scientific capabilities."
